 These asthma medications, with the exception of an inhaled corticosteroidlong-acting beta2-agonist combination product and Xolair, may be continued during the run-in period of the study between Visits 1 and 2, but must be withheld prior to Visit 2 for the appropriate exclusion period as shown below. 